Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

NCT04906382 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Sponsor reorganization

Conditions

Lynch Syndrome
Recurrent Endometrial Carcinoma
Recurrent Endometrial Clear Cell Adenocarcinoma
Recurrent Uterine Corpus Carcinosarcoma
Mismatch Repair Deficiency
Recurrent Endometrial Cancer
Metastatic Endometrial Cancer

Interventions

PROCEDURE: Biopsy
DRUG: Carboplatin
DRUG: Paclitaxel
BIOLOGICAL: Tislelizumab

Sponsor

Floor Backes, MD